[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Rew et al., 1991 - Google Patents

Proliferation characteristics of human colorectal carcinomas measured in vivo

Rew et al., 1991

Document ID
6666929571986659982
Author
Rew D
Wilson G
Taylor I
Weaver P
Publication year
Publication venue
Journal of British Surgery

External Links

Snippet

The cell proliferation kinetics of 100 human colonic and rectal adenocarcinomas have been studied in vivo by bromodeoxyuridine infusion and multiparameter flow cytometry. A total of 97 patients, three with synchronous tumours, consented to receive a single bolus dose of …
Continue reading at academic.oup.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins

Similar Documents

Publication Publication Date Title
Rew et al. Proliferation characteristics of human colorectal carcinomas measured in vivo
Witzig et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma
Cindolo et al. Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database
Nordsmark et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study
Kubota et al. Ki‐67‐determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: a multivariate analysis
Kokal et al. Tumor DNA content in resectable, primary colorectal carcinoma
Maier et al. The clinical value of urinary cytology: 12 years of experience with 615 patients.
Ten Velde et al. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer
Kroll et al. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma
Ohyama et al. Proliferative activity and malignancy in human gastric cancers. Significance of the proliferation rate and its clinical application
Jaafari-Ashkavandi et al. MCM3 and Ki67 proliferation markers in odontogenic cysts and ameloblastoma
Harlow et al. Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonic adenocarcinomas
Schiepers et al. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma
Enker et al. DNA/RNA content and proliferative fractions of colorectal carcinomas: a five-year prospective study relating flow cytometry to survival
Taylor et al. Flow cytometric DNA analysis of adrenocortical tumors in children
Bai et al. Nomogram to predict incomplete cytoreduction for pseudomyxoma peritonei
Kaplan Progress in thyroid cancer
Wang et al. The use of platelet/lymphocyte ratio and cancer antigen 125 combined with magnetic resonance diffusion-weighted imaging in diagnosis of recurrent ovarian cancer and neuropathic pain
Heimann et al. Significance of DNA content abnormalities in small rectal cancers
Martin et al. DNA content as a prognostic index in gestational trophoblastic neoplasia
Lin et al. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging
Hermansen et al. Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin)
Petrelli et al. The utility of squamous cell carcinoma antigen for the follow‐up of patients with squamous cell carcinoma of the anal canal
Ellis et al. The content of tumor DNA as an indicator of prognosis in patients with T1N0M0 and T2N0M0 carcinoma of the breast
Rew GD zyxwvutsrqponmlkjihg